AKTX — Akari Therapeutics Share News
0.000.00%
Last trade - 00:00UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics
Brief: Akari Therapeutics - Files To Offer Up To 2.5 Million Adss Via White Lion Capital - SEC Filing
NASDAQ RESUMED AT 10:05 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM
NASDAQ RESUMED AT 11:22 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:17 AM
NASDAQ RESUMED AT 10:05 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:00 AM
NASDAQ RESUMED AT 10:00 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM
NASDAQ RESUMED AT 09:54 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:49 AM
NASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
NASDAQ RESUMED AT 03:38 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:33 PM